Medtronic plc (MDT)
Is the Options Market Predicting a Spike in Medtronic Stock?
Investors need to pay close attention to MDT stock based on the movements in the options market lately.
Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years
For an investor in their 50s or 60s who is finished chasing trends, Medtronic (NYSE:MDT | MDT Price Prediction) is a stock worth owning for decades because it pairs inelastic demand for medical devices with a 49th consecutive year of dividend increases.
Dividend Announcements: May 30-June 5, 2026
In this article series, I summarize dividend announcements of the past week. Six stocks in my database announced dividend increases, including one stock I own, and one declared a special dividend. W. R. Berkley stands out with an 11.1% dividend increase, a 50¢ special dividend, and the highest quality score this week. Medtronic offers the most value, trading 9% below fair value, but its dividend growth is modest at 1.4%.
Medtronic Bets on Ablation, Robotics, and Hypertension
MDT is betting on ablation, robotics and hypertension therapies as next growth drivers, but tariffs, FX and pricing pressures cloud near-term upside.
Is Medtronic Stock a Buy at 14x Forward Earnings?
MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.
Medtronic: A Dividend Aristocrat At A Steal Now
Medtronic plc is a sleepy Dividend Aristocrat with the potential for dividend growth to reaccelerate in the next 12 to 24 months. MDT beat the analyst consensus for revenue and non-GAAP EPS in Q4 2026, with the highest annual revenue growth in 10 years. Medtronic sports an A S&P credit rating with a stable outlook.
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Medtronic Bottoms, Healthy Rebound Ahead
Medtronic's NYSE: MDT primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were inherently strong and expected to remain so.
MDT Q4 Earnings Call Points to Another Year of Growth
MDT touts FY26 as a turning point, keeps FY27 growth targets high, and spotlights CAS and new platforms as investors press on tariffs and TAVR.
Medtronic Q4 Earnings and Revenues Beat, Stock Rises in Pre-Market
MDT tops Q4 revenue and earnings estimates as Cardiovascular strength and Cardiac Ablation growth fuel results, while FY27 guidance points higher.
Medtronic (MDT) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic Q4 Earnings Call Highlights
Medtronic NYSE: MDT reported what executives described as its strongest top-line performance in a decade, as growth in cardiac ablation, diabetes, medical-surgical products and select neuroscience platforms helped drive fiscal fourth-quarter and full-year results above expectations.
